Shane Ali Dungersi*, Vijayakumar Narayanan and James Mbogo
Primary esophageal and esophagogastric junction tumors are a common group of tumors in Africa with a high incidence in Kenya. Chemotherapy and radiotherapy are the main therapy options for advanced inoperable tumors. However, immune checkpoint inhibitor therapy is gaining prominence in this group of tumors. Tumors with high PD-1/PD-L1 expression, high microsatellite instability, and negative Herceptin status are the most beneficiaries of ICI therapy. Several studies outlined the first-line as well as second-line use of ICI therapy in this group of tumors. We are presenting a case of a locally advanced inoperable tumor, successfully treated with combined modality therapy including concurrent chemo radiotherapy followed by short-course adjuvant immunotherapy in a lower esophageal, esophagogastric junction tumor. The patient remained in complete response for two years since completion of therapy and is on close follow-up.